<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9617">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05694260</url>
  </required_header>
  <id_info>
    <org_study_id>1002-041</org_study_id>
    <nct_id>NCT05694260</nct_id>
  </id_info>
  <brief_title>A Phase 2 Clinical Study in Children With HeFH Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing</brief_title>
  <acronym>CLEAR Path 1</acronym>
  <official_title>An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bempedoic Acid in Pediatric Patients (6 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Esperion Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Esperion Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple-dose study to measure PK, PD and safety of bempedoic acid in pediatric patients 6 to&#xD;
      17 years of age with HeFH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dose-selection based on body weight will be determined for use in pediatric clinical&#xD;
      development&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2023</start_date>
  <completion_date type="Anticipated">May 24, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 24, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observed pharmacokinetics - trough plasma concentration of ETC-1002</measure>
    <time_frame>8 weeks of steady-state dosing</time_frame>
    <description>observed trough plasma concentration of ETC-1002</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Model-based pharmacokinetics - AUC, ss</measure>
    <time_frame>8 weeks of steady-state dosing</time_frame>
    <description>Model-based area under the plasma concentration-time curve (AUC,ss)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Model-based pharmacokinetics - Cavg, ss</measure>
    <time_frame>8 weeks of steady-state dosing</time_frame>
    <description>Model-based average plasma concentration (Cavg,ss)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Model-based pharmacokinetics - Cmax, ss</measure>
    <time_frame>8 weeks of steady-state dosing</time_frame>
    <description>Model-based maximum plasma concentration (Cmax,ss)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exposure/LDL-C response relationship</measure>
    <time_frame>8 weeks of steady-state dosing</time_frame>
    <description>ETC-1002 dose and exposure/LDL-C-lowering response relationship</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in LDL-C</measure>
    <time_frame>8 weeks of steady-state dosing</time_frame>
    <description>Percent change from baseline to Week 8 in LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>8 weeks of steady-state dosing</time_frame>
    <description>Observed adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients at 16 to &lt;30 kg body weight at screening receiving once daily 60 mg bempedoic acid for 8 weeks followed by 90 mg bempedoic acid for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients at 30 to 60 kg body weight at screening receiving once daily120 mg bempedoic acid for 8 weeks followed by 150 mg bempedoic acid for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients at greater than 60 kg body weight at screening receiving once daily 180 mg bempedoic acid for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bempedoic acid</intervention_name>
    <description>Once daily oral dosing with oral tablets or oral suspension.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>ETC-1002</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Written informed consent and assent (where applicable) Aged 6-17 years old Diagnosis of&#xD;
        HeFH (heterozygous familial hypercholesterolemia) Treatment with approved stable lipid&#xD;
        modifying therapies Fasting LDL-C greater than or equal to 130 mg/dL (3.4 mmol/L)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Diagnosis of HoFH (homozygous familial hypercholesterolemia) or compound HeFH Fasting&#xD;
        Triglyceride greater than or equal to 400 mg/dL (4.5 mmol/L) Type 1 or Type 2 diabetes or&#xD;
        newly diagnosed impaired glucose tolerance Women/girls who are pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Louie, MD</last_name>
    <role>Study Director</role>
    <affiliation>Esperion Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esperion Medical Information</last_name>
    <phone>833-377-7633</phone>
    <email>medinfo@esperion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Continental Clinical Solutions</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 808</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, Division of Endocrinology, Metabolism and Lipid Research.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 801</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 803</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 804</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah and Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 806</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital - Stollery Children's Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 102</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ecogene-21</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 103</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 201</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinder- und Jugendkrankenhaus AUF DER BULT</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 301</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC - Locatie AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 401</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 G</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 402</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli - Hospital de Sabadell</name>
      <address>
        <city>Barcelona</city>
        <zip>8208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 602</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <zip>8950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 606</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Jerez de la Frontera</name>
      <address>
        <city>Cadiz</city>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 603</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 607</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Abente y Lago</name>
      <address>
        <city>La Coruña</city>
        <zip>15001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 601</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Site Coordinator 608</last_name>
      <email>medinfo@esperion.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>January 12, 2023</study_first_submitted>
  <study_first_submitted_qc>January 12, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2023</study_first_posted>
  <last_update_submitted>May 9, 2023</last_update_submitted>
  <last_update_submitted_qc>May 9, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>HeFH</keyword>
  <keyword>LDL-cholesterol</keyword>
  <keyword>ETC-1002</keyword>
  <keyword>Adenosine triphosphate citrate lyase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The Investigator must ensure that the patient's confidentiality is maintained. The names and identities of all research patients will be kept in strict confidence and will not appear on eCRFs or other records that are provided to or retained by the Sponsor (or designee). If a patient's name appears on any document, it must be redacted and replaced with the patient identifier before a copy of the document is supplied to the Sponsor (or designee). The ICF must include appropriate statements explaining that patient data will be confidential and the actions that will be taken to ensure patient confidentiality.&#xD;
Any other confidentiality requirements specified by the site, IRB or IEC, or national or local regulations will be adhered to and detailed appropriately in the ICF.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

